Get the Stockscreener App
19.19
5.51%
-1.12
After Hours:
19.16
-0.03
-0.16%
Dyne Therapeutics Inc stock is traded at $19.19, with a volume of 5.14M.
It is down -5.51% in the last 24 hours and down -26.90% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$20.31
Open:
$19.38
24h Volume:
5.14M
Relative Volume:
2.10
Market Cap:
$3.58B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-5.9484
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
-23.67%
1M Performance:
-26.90%
6M Performance:
+8.48%
1Y Performance:
+44.83%
1-Day Range:
$18.97
$20.16
1-Week Range:
$17.00
$25.39
52-Week Range:
$11.92
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.19 | 3.79B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Yahoo Finance
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - Stock Titan
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
Why is Dyne Therapeutics stock plummeting today? By Investing.com - Investing.com Nigeria
Why is Dyne Therapeutics stock plummeting today? - Investing.com
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo Finance
Dyne Therapeutics (NASDAQ: DYN) officer plans $121,745 share sale - Stock Titan
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting - Investing News Network
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting - The Manila Times
Dyne Therapeutics Announces Preclinical Data Supporting Four DMD Exon-Skipping Candidates Advancing Into IND-Enabling Studies - Quiver Quantitative
Four experimental treatments for Duchenne muscular dystrophy move toward human testing - Stock Titan
Dyne Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - news.stocktradersdaily.com
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story - Sahm
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst - MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):